FDA Brief

Warning letters Drugs

FDA warning letter to

Formology Lab Inc.

High riskIssued Mar 1, 2023Posted Mar 14, 2023Division of Pharmaceutical Quality Operations IV

FDA warned Formology Lab Inc. about manufacturing rule violations for drugs, including untested ingredients and unvalidated sunscreen processes.

What happened

FDA inspected Formology Lab Inc.'s drug manufacturing facility in Chatsworth, California, from August 30 to September 9, 2022. The agency found that the company released drug batches before testing ingredient identity, lacked process validation for OTC sunscreen drugs, did not test manufacturing water for conductivity and total organic carbon, and had an inadequate quality unit and stability program.

What FDA found

  1. The company failed to test each incoming active ingredient for identity before use and released batches before identity testing was done.

    21 CFR 211.84(d)(1)
  2. The company lacked written production and process control procedures and could not show that its OTC sunscreen manufacturing processes were validated.

    21 CFR 211.100(a)
  3. The company could not show its manufacturing water met the USP monograph because it did not perform conductivity and total organic carbon testing.

    21 CFR 211.100(a)
  4. The company's quality unit lacked written procedures for investigations, changes, complaints, training, corrective actions, deviations, and annual product reviews.

    21 CFR 211.22(a) and (d)
  5. The company did not have enough stability data for each drug product and did not adequately investigate out-of-specification viscosity results.

    21 CFR 211.22(a) and (d)

What FDA wants

FDA tells Formology to correct the violations promptly and respond in writing within 15 working days with reviews and remediation plans for its material system, process validation, water system, quality unit, and stability program. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.

Who should pay attention

  • brands that use Formology as a contract manufacturer
  • distributors and retailers selling OTC sunscreen drugs made by the firm
  • quality teams at drug companies that rely on supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk